Supplemental Digital Content 1: clinical and laboratory findings of three cases.

|  |  |  |  |
| --- | --- | --- | --- |
|  | Case 1 | Case 2 | Case 3 |
| Age (mo.) / Sex | 26/F | 14/F | 18/F |
| AST (IU/L) | 2,175 | 12,358 | 134 |
| ALT (IU/L) | 1,069 | 7,304 | 124 |
| LDH (IU/L) | 3,368 | 13,456 | 434 |
| Glucose (mg/dL) | 397 | NT | 253 |
| WBC (/mL) | 8,000 | 11,200 | 4,000 |
| Hb (g/dL) | 12.5 | 11.6 | 10.6 |
| Platelet (x104/mL) | 5.3 | 12.0 | 19.9 |
| PT-INR | 2.27 | 1.99 | 1.36 |
| APTT (sec.) | 54.8 | 44.5 | 30.4 |
| FDP (mg/mL) | 68 | 126 | 8 |
| Ferritin (ng/mL) | 9,554 | 11,591 | 420 |
| CSF cells (/mL) | NT | 6 | 1 |
| CSF glucose (mg/dL) | NT | 64 | 200 |
| CSF protein (mg/dL) | NT | NT | NT |
| HHV-6 DNA (blood)\* | 4.4x103 /mL | 2.8x103  | 3.9x102  |
| HHV-6 DNA (CSF) | NT | 6.0x102 /mL | Not detected |
| Anti-HHV-6 IgG (FA) |  |  |  |
|  Acute phase | - | < 1:10 | 1:20 |
|  Convalescent phase | 1:40 | 1:80 | 1:160 |
| *CPT2* variation | Homozygous352F and V368I | F352C (hetero.)andV368I (homo.) | Homozygous352F and V368I |
| Sequelae | Brain death | Spastic quadriplegia, epilepsy, and mental retardation | Spastic quadriplegia, epilepsy, and mental retardation |

The laboratory data were observed during day 1 to 3 of admission.

NT: not tested, FDP: fibrin degradation product, CSF: cerebrospinal fluid, FA: fluorescent antibody method

\*HHV-6 DNA was quantified in the serum (Case 1) and in whole blood (Case 2 and Case 3; copy numbers are noted as copies per 1x106 leukocytes).